Comparison Results | RestoredCDC.org

Comparison timestamp: 2025-05-03 17:05:42 UTC
RestoredCDC URL: http://restoredcdc.org/www.cdc.gov/pneumococcal/php/drug-resistance/index.html
Live cdc.gov URL ↗: https://www.cdc.gov/pneumococcal/php/drug-resistance/index.html
Removed: Line removed from cdc.gov. Specific word removals are highlighted.
Added: Line added to cdc.gov. Specific word additions are highlighted.
Injected: Line or disclaimer added by RestoredCDC.org.
Unchanged: Line unchanged.
Enable word-level highlighting (experimental)? High contrast mode
    Original site: www.cdc.gov/pneumococcal/php/drug-resistance/index.html | RestoredCDC.org is an independent project, not affiliated with CDC or any federal entity. Visit CDC.gov for free official information. Due to archival on January 6, 2025, recent outbreak data is unavailable. Videos are not restored. Access data.restoredcdc.org for restored data. Use of this site implies acceptance of this disclaimer.
    [More]
    About Us Report Bug Compare Content
  Skip directly to site content Skip directly to search Skip directly to On This Page
          An official website of the United States government
        Here's how you know
              Official websites use .gov
              A .gov website belongs to an official government organization in the United States.
              Secure .gov websites use HTTPS
              A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.
        Pneumococcal Disease
          Explore Topics
        Search
          Search
          Clear Input
        For Everyone
          * About
          * Symptoms and Complications
          * How It Spreads
          * Vaccination
          * Disease in Adults
          * View all
        Health Care Providers
          * Clinical Overview
          * Clinical Guidance
          * Clinical Features
          * Vaccine Recommendations
          * View all
        Public Health
          * Surveillance and Trends
          * Drug Resistance
          * View all
          Related Topics:
            Pneumonia
        View All
      search close search
          search
    Pneumococcal Menu Close
    Pneumococcal Menu
          search
              For Everyone
                  * About
                  * Symptoms and Complications
                  * How It Spreads
                  * Vaccination
                  * Disease in Adults
                  * View All Home
              Health Care Providers
                  * Clinical Overview
                  * Clinical Guidance
                  * Clinical Features
                  * Vaccine Recommendations
                  * View All
              Public Health
                  * Surveillance and Trends
                  * Drug Resistance
                  * View All
              Related Topics
                  * Pneumonia
        View All Pneumococcal
    Surveillance and Trends Drug Resistance View All
December 17, 2024
  Antibiotic-resistant Streptococcus pneumoniae
          Key points
            * Some Streptococcus pneumoniae isolates are resistant to one or more antibiotics.
            * S. pneumoniae resistance can lead to treatment failures.
            * Vaccination helps prevent resistant pneumococcal infections.
        Trends
        How common antibiotic-resistant S. pneumoniae is varies throughout the United States.
        Today, S. pneumoniae resistant to at least one antibiotic causes more than 2 in 5 infections. New pneumococcal vaccines will be critical as the proportion of resistance to some important antibiotics continues to increase.
          View Larger
          The proportion of IPD not susceptible to some important antibiotics has increased over time.
        The proportion of IPD not susceptible to select antibiotics has remained relatively steady over time.
        Threats report
        CDC's Antibiotic Resistance Threats in the United States, 2019 identifies antibiotic-resistant S. pneumoniae as a serious threat. The report includes the latest national death and infection estimates that underscore the continued threat of antimicrobial resistance.
          Keep Reading: Antibiotic Resistance Threats in the United States, 2019
          Bact Facts Interactive
              You can analyze and visualize data on antibiotic-resistant S. pneumoniae.
                Use Bact Facts Interactive
        Vaccine impact
        Pneumococcal vaccines provide serotype-specific protection. Pneumococcal conjugate vaccines (PCVs) include protection against serotypes that cause the majority of antibiotic-resistant invasive pneumococcal disease (IPD). As a result, introduction of PCVs caused a significant reduction in resistant IPD in the United States.
        The number of antibiotic-nonsusceptible IPD cases also decreased greatly following a change in definition of non-susceptibility (resistance) to penicillin in 2008.
          Timeline of CDC's PCV recommendations
              PCV7: 2000 in children
              PCV13: 2010 in children; 2012 in adults with risk conditions; 2014-2019 in adults 65 years or older
              PCV15: 2021 in adults; 2022 in children
              PCV20: 2021 in adults; 2023 in children
              PCV21: 2024 in adults
        PCVs have reduced pneumococcal infections caused by vaccine serotypes, most of which were resistant to antibiotics. Invasive pneumococcal infections caused by vaccine serotypes have decreased by 90% in children and 60% in adults.
        Before 2000: Seven serotypes caused most antibiotic-resistant S. pneumoniae in the United States. They were 6A, 6B, 9V, 14, 19A, 19F, and 23F. Rates of disease caused by these serotypes (except 19A) decreased after the introduction of PCV7. PCV7 included six of the seven (not 19A) serotypes.
        Between 2000 and 2010: Rates of disease and antibiotic-resistant S. pneumoniae caused by serotype 19A increased. However, rates of disease caused by serotype 19A have greatly decreased since then due to use of PCV13 (includes 19A). No new serotype causing most antibiotic-resistant IPD has emerged in its place in the United States.
        The impact PCV15, PCV20, and PCV21 will have on antibiotic-resistant pneumococcal serotypes is yet to be determined.
        Surveillance
        CDC uses U.S. surveillance data to estimate how many cases of invasive pneumococcal disease (including resistant cases) occur each year.
          Keep Reading: Surveillance and Trends
        Several private-sector systems also track antibiotic-resistant S. pneumoniae.
        Outbreaks
        State and local health departments have reported outbreaks of antibiotic-resistant S. pneumoniae in long-term care settings and childcare centers.
        Risk groups
        People with pneumococcal infections who recently used antibiotics are more likely to have a resistant infection than those who haven't.
        People who attend or work at childcare centers are at increased risk for infection with antibiotic-resistant S. pneumoniae.
        Other risk factors for having a resistant S. pneumoniae infection include hospitalization and immunosuppression.
        Costs
        Antibiotic-resistant S. pneumoniae is associated with increased costs compared to infections caused by non-resistant (susceptible) pneumococcus. This is because of
          * More expensive antibiotics needed
          * Costs associated with antibiotic drug development
          * Surveillance costs to track resistance patterns
          * Repeat disease due to treatment failures
          * Educational requirements for patients, clinicians, and microbiologists
        Challenges and opportunities
        Challenges
        There are several factors that create challenges for preventing emerging antibiotic resistance of pneumococcus, including:
          * Unnecessary use of antibiotics
          * Nonuniversal adoption of standard methods (CLSI guidelines) to identify and define antibiotic-resistant S. pneumoniae
          * Spread of resistant serotypes
          * Lack of a vaccine that can protect against all serotypes of pneumococcus
        Opportunities
        Improving appropriate antibiotic use and expanding use of pneumococcal vaccines may slow or reverse emerging antibiotic resistance. Expanded use of recommended vaccines could also prevent more infections.
        Resources
        Active Bacterial Core surveillance (ABCs): Surveillance reports
        National Notifiable Diseases Surveillance System (NNDSS)
        Be Antibiotics Aware partner toolkit
        Antimicrobial resistance
        On This Page
            * Trends
            * Vaccine impact
            * Surveillance
            * Outbreaks
            * Risk groups
            * Costs
            * Challenges and opportunities
            * Resources
          Related PagesSurveillance and Trends
          Related Pages
        * 
        Back to Top
            * Surveillance and Trends
          View All Pneumococcal
    Surveillance and Trends
  December 17, 2024
      Sources Print Share
        Facebook LinkedIn Twitter Syndicate
          Content Source:
        National Center for Immunization and Respiratory Diseases; Division of Bacterial Diseases
      Related PagesSurveillance and Trends
      Related Pages
    * 
 
        * Surveillance and Trends
      View All Pneumococcal
  Back to Top
    Pneumococcal
    Pneumococcal disease is caused by bacteria that commonly live in the nose and throat and cause both mild (ear infections) and serious infections (pneumonia).
    View All
        For Everyone
          * About
          * Symptoms and Complications
          * How It Spreads
          * Vaccination
          * Disease in Adults
          Health Care Providers
            * Clinical Overview
            * Clinical Guidance
            * Clinical Features
            * View All
          Public Health
            * Surveillance and Trends
            * Drug Resistance
        Sign up for Email Updates
    Contact Us
        Contact Us
          * Call 800-232-4636
          * Contact CDC
    About CDC
        About CDC
          * Pressroom
          * Organization
          * Budget & Funding
          * Careers & Jobs
    Policies
              * Accessibility
              * External Links
              * Privacy
              * Web Policies
              * FOIA
              * OIG
              * No Fear Act
              * Nondiscrimination
              * Vulnerability Disclosure Policy
    Languages
            Languages
              * Español
            Language Assistance
                  * Español
                  * 繁體中文
                  * Tiếng Việt
                  * 한국어
                  * Tagalog
                  * Русский
                  * العربية
                  * Kreyòl Ayisyen
                  * Français
                  * Polski
                  * Português
                  * Italiano
                  * Deutsch
                  * 日本語
                  * فارسی
                  * English
    Archive
          * CDC Archive
          * Public Health Publications
    Contact Us
      Contact Us
        * Call 800-232-4636
        * Contact CDC
    About CDC
        * Pressroom
        * Organization
        * Budget & Funding
        * Careers & Jobs
        * About CDC
    Policies
        * Accessibility
        * External Links
        * Privacy
        * Web Policies
        * FOIA
        * OIG
        * No Fear Act
        * Nondiscrimination
        * Vulnerability Disclosure Policy
    Languages
      Languages
        * Español
      Language Assistance
        * Español
        * 繁體中文
        * Tiếng Việt
        * 한국어
        * Tagalog
        * Русский
        * العربية
        * Kreyòl Ayisyen
        * Français
        * Polski
        * Português
        * Italiano
        * Deutsch
        * 日本語
        * فارسی
        * English
    Archive
        * CDC Archive
        * Public Health Publications
    HHS.gov USA.gov
Note: Comparison ignores leading/trailing whitespace and certain script/tracking codes. Word-level highlighting (optional above) only applies to changed lines.